NRX Pharmaceuticals, Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Jonathan Javitt (CEO) and Michael Abrams (CFO) issued standard Sarbanes-Oxley Section 302 and 906 certifications as of August 14, 2026 for the quarter ended June 30, 2026. Both officers certified that the 10-Q fairly presents financial condition and results of operations and that disclosure controls and internal controls over financial reporting are effective. No specific financial data, material weaknesses, or operational changes are mentioned in these certification exhibits.
Why this rating
Routine SOX compliance certifications; no substantive business or financial event disclosed. Standard quarterly filing requirement.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.